Safety events in kidney transplant recipients: results from the folic Acid for vascular outcome reduction in transplant trial.

ABSTRACT:

Background

Kidney transplant recipients are at increased risk for adverse safety events related to their reduced renal function and many medications.

Methods

We determined the incidence of adverse safety events based on previously defined Agency for Healthcare and Research Quality (AHRQ) International Classification of Diseases-9 (ICD-9) code-derived patient safety indicators (PSI) in the Folic Acid for Vascular Outcome Reduction in Transplant trial participants who had a hospitalization stratified by tertiles of estimated glomerular filtration rate (GFR). We also examined the frequency of Micromedex defined two precautionary drug-drug interactions, and two medications whose use may be contraindicated because of reduced GFR from the Folic Acid for Vascular Outcome Reduction

SUBMITTER: Weir MR 

PROVIDER: S-EPMC4469189 | biostudies-literature | 2015 May

REPOSITORIES: biostudies-literature